SpringWorks Therapeutics IPO

9/12/2019

IPO

$162,000,000

Proceeds will be used as follows: approximately $60 million to $70 million to fund our ongoing Phase 3 DeFi trial of nirogacestat in patients with desmoid tumors and, if the results from this trial are favorable, to file for regulatory approval in the United States and select international markets; approximately $50 million to $60 million to fund our upcoming Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN and, if the results from this trial are favorable, to file for regulatory approval in the United States and select international markets; approximately $10 million to $15 million to fund our ongoing Phase 1b trial of mirdametinib and lifirafenib and, if initial results are favorable, to fund additional expansion cohorts; approximately $25 million to $35 million to further develop our lead product candidates as standalone or combination therapies in new oncology and rare disease indications; and the remainder, if any, for working capital, general corporate purposes and to

Publicly-held

Biopharmaceutical

100 Washington Blvd.
Stamford, CT 06902
USA

SpringWorks Therapeutics (Nasdaq: SWTX) is a different type of therapeutic development company purpose-built for the 21st century. SpringWorks Therapeutics is on a mission to connect scientists, biopharmaceutical partners, patient groups, funders and philanthropists to deliver promising, transformative science to underserved patients.